Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 2 juni att bolagets konvertibla lån...
Lucky Games har publicerat bolagets delårsrapport för det första kvartalet år 2024 och visar på fort...
Despite lowering our short-term forecasts, Redeye retains its positive stance on Speqta following th...
IRLAB Therapeutics is swiftly progressing with the Phase I trial for IRL757, with the first particip...
Redeye updates its estimates and valuation following Freemelt’s Q1 report, which fell below expectat...
Redeye comments on the subscription price and the strong start of the Terclara launch.
Q1: sales SEK 0.82m, adj. EBIT -12m, no deliveries Q2 to be more eventful, SEK 12m of orders announc...
PTS has published new statistics for the SE fibre market BRE2 market share: slightly down versus 202...
Redeye comments on the positive outcome of Annexin’s rights issue.
Redeye leaves a comment following the announced merger between Magle Group and Amniotics yesterday.
Redeye comments on Ngenic’s Q1 report, which was in line with the preliminary figures communicated e...
Suominen has today announced a restructuring programme that is expected to generate EUR 1.
Redeye saw a Q1 report showing sales slightly below our estimates, with a total growth of 18% for th...
Redeye sees a mixed Q1 report where ARR growth accelerates q/q but comes somewhat short of our expec...
We visited Borås Tapetfabrik on Wednesday We assess there is limited technological risk for traditio...
